
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) on Monday announced a private investment in public equity of 212 million shares at $1.00 per share, representing a premium of 11.5% from the closing price of the stock on November 21, 2025.
The company expects gross proceeds of approximately $212 million (funded in a combination of $USD and USDT).